Tocilizumab: A Review in Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Tocilizumab: A Review in Rheumatoid Arthritis

Published:2017-11 Issue:17 Volume:77 Page:1865-1879
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-017-0829-7/fulltext.html

Reference75 articles.

1. Dhillon S. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. BioDrugs. 2014;28(1):75–106.

2. European Medicines Agency. Tocilizumab (RoActemra) 20 mg/mL concentrate solution for infusion/162 mg solution for injection in pre-filled syringe: summary of product characteristics. 2016. http://www.ema.europa.eu . Accessed 2 Oct 2017.

3. European Medicines Agency. EPAR summary for the public: RoActemra (tocilizumab). 2017. http://www.ema.europa.eu . Accessed 4 Oct 2017.

4. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.

5. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.

Cited by 306 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin receptor therapeutics attenuate inflammation in canine synovium following cruciate ligament injury;Osteoarthritis and Cartilage;2024-10

2. Evaluation of tocilizumab-induced hypofibrinogenemia in rheumatology practice: a retrospective, real-life, single-center experience;Rheumatology International;2024-09-12

3. Single nucleotide polymorphisms in the development of osteomyelitis and prosthetic joint infection: a narrative review;Frontiers in Immunology;2024-09-05

4. Interleukin-6 receptor antagonists in pregnancy: a reason for cautious optimism;The Lancet Rheumatology;2024-09

5. Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab;Infection;2024-08-29